CollPlant and Stratasys to begin pre-clinical study with printed implants

CollPlant Biotechnologies (CLGN) and Stratasys (SSYS) announced the initiation of a pre-clinical study with 200cc commercial-sized regenerative implants printed on a Stratasys Origin 3D printer. The collaboration between CollPlant and Stratasys is currently focused on the development of a bioprinting solution for CollPlant’s breast implants, in addition to finding solutions to scale-up the implant’s fabrication process. The study is intended to test the ability of the implants to promote the growth of natural breast tissue and completely degrade over time. Stratasys is a leader in polymer 3D printing solutions and CollPlant is a pioneering regenerative and aesthetics medicine company developing innovative technologies and products based on its rhCollagen for tissue regeneration and organ manufacturing.